Current topics in diagnosis and treatment of tinea unguium in Japan

Journal of Dermatology

Volumn 26, Issue 2, 1999, Pages 87-97

  Tanuma, Hiroyuki ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Diagnosis; Japan; Tinea unguium; Treatment

Indexed keywords

AMOROLFINE; ANTIFUNGAL AGENT; CICLOPIROXOLAMINE; ECONAZOLE; FLUCONAZOLE; GRISEOFULVIN; ITRACONAZOLE; KERATOLYTIC AGENT; NETICONAZOLE; PETROLATUM; SULCONAZOLE; TERBINAFINE; TIOCONAZOLE; UREA;

ABRASION; ADULT; CLINICAL TRIAL; DERMATOPHYTE; DRUG EFFICACY; EXTRACTION; FEMALE; FUNGUS CULTURE; HISTOPATHOLOGY; HUMAN; JAPAN; MALE; OINTMENT; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PREVALENCE; PROTECTIVE CLOTHING; REVIEW; TOPICAL DRUG ADMINISTRATION;

EID: 0033066504     PISSN: 03852407     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1346-8138.1999.tb03517.x     Document Type: Review

References (79)

1. Higashi U: Tinea unguium and other types of onychomycosis, in Imamura S, Ogawa H, Watanabe S (eds): Dermatology Mook No. 11, Kanehara Shuppan, Tokyo, 1988, pp 141-146. (in Japanese)
2. Takizawa K: Tinea unguium, in Yamamura Y, Kukita A, Sano M, Seiji M (eds), Modern Dermatology Series, Vol. 7B, Nakaya Shoten, Tokyo, 1982, pp 59-70. (in Japanese)
3. Epidemiological Investigation Committee for Human Mycoses in the Japanese Society for Medical Mycology: 1992 Epidemiological Survey of Dermatomycoses in Japan, Jpn J Med Mycol, 36: 87-95, 1995. (in Japanese)
4. Tanuma H: Treatment of hyperkeratotic tinea pedis, rinsho derma (Tokyo), 37: 1939-1946, 1995. (in Japanese)
5. Kusunoki T: Study on tinea unguium, Jpn J Med Mycol, 16: 165-176, 1975 (in Japanese)
6. Takahashi Y, Takahashi S, Miura O, Fukushi A: Tinea unguium in children - With special reference to association with systemic diseases, rinsho derma (Tokyo), 3: 683-689, 1961. (in Japanese)
7. Tanuma H: Evaluation of histological findings and differential diagnosis - Inflammatory skin diseases (12) - Fungal infections (I) - Superficial dermatomycosis, Pathology and Clinical Medicine, 9: 647-652, 1991.
8. Nishiyama S: Onychomycosis, in Nishiyama S (ed): Ungual Disease Color Atlas, Nankodo, Tokyo, 1993, pp 187-191. (in Japanese)
9. Zaias N: Onychomycosis, Arch Dermatol, 105: 263-274, 1972.
10. Watanabe S: Tinea unguium, Watanabe S (ed): Dermatomycosis Prone to Wrong Diagnosis, Kanehara Shuppan, Tokyo, 1992, pp 101-103. (in Japanese)
11. Tanuma H, Nishiyama S: Diagnosis of Dermatomycosis, Sandoz Pharmaceutical Co., Ltd., Tokyo, 1994, p 17.
12. Korting HC, Korting MS: Is tinea unguium still widely in curable? A review three decades after the introduction of griseofulvin, Arch Dermatol, 128: 243-248, 1992.
13. Doncker PD: Pharmacokinetics: Basis for research in fungal nail disease, Med Monitor, 1: 6-7, 1994.
14. Matthieu L, Doncker P De, Cauwenbergh G, et al: Itraconazole penetrates the nail via the nail matrix and the nail bed - An investigation in onychomycosis, Clin Exp Dermatol, 16: 374-376, 1992.
15. Willemsen M, Doncker P De, Willem J, et al: Posttreatment itraconazole levels in the nail, J Am Acad Dermatol, 26: 731-735, 1992.
16. Lavrijsen AMP, Balmas KJ, Nugteren-Huying WM, Roldaan AC, van't Wout JW, Stricker BHCh: Hepatic injury associated with itraconazole, Lancet, 340: 251-252, 1992.
17. Hann SK, Kim JB, Im S, Han KH, Park YK: Itraconaxole-induced acute hepatitis, Br J Dermatol, 129: 500-501, 1993.
18. Hay RJ: Risk/benefit ratio of modern antifungal therapy: Focus on hepatic reactions, J Am Acad Dermatol, 29: s50-s54, 1993.
19. Crane JK, Shih HT: Syncope and cardiac arrthythmia due to an interaction between itraconazole and terfenadine, Am J Med, 95: 445-446, 1993.
20. Pohjola-Sintonen S, Viitasalo M, Toivonen L, Neuvoene P: Itraconazole prevents terfenadine metabolism and increases risk of torsades de pointes ventricular tachycardia, Eur J Clin Pharmacol, 45: 191-193, 1993.
21. Zechnich AD, Hedges JR, Eise It-Proteau D, Haxby D: Possible interactions with terfenadine or astemizole, West J Med, 160: 321-325, 1994.
22. WHO Drug Information: Non-sedating Antihistamine and Cardiac Arrthythmias, 6: 165-166, 1992.
23. Varhe A, Olkkola KT, Neuvonen PJ: Pharmacokinetics and drug disposition: Oral triazolam is potentially hazardous to patients receiving systemic antimycotics ketoconazole or itraconazole, Clin Pharm Ther, 56: 601-607, 1994.
24. Honig PK, Wortham DC, Hull R, Zamani K, Smith JE, Catilena LR: Itraconazole affects single-dose terfenadine pharmacokinetics and cardiac repolarization pharmycodynamics, J Clin Pharmacl, 33: 1201-1206, 1993.
25. Itraconazole Study Group in the Dermatological Field: Clinical evaluation of itraconazole, a new oral antifungal agent, for tinea unguium, ungual candidiasis, onychia due to Candida spp, and perionychia, The Clinical Report, 25: 433-448, 1991.
26. Doncker P De, Lint JV, Docky P, Roseeuw O: Pulse therapy with one-week itraconazole monthly for three or four months in the treatment of onychomycosis, Cutis, 56: 180-183, 1995.
27. Doncker PD, Decoix T, Pierard GE: Antifungal pulse therapy for onychomycosis. A pharmacokinetics and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole, Arch Dermatol, 132: 34-41, 1996.
28. Hiruma S, Banba K, Noguchi H, Kawada A, Ishibashi A: Itraconazole pulse therapy for tinea unguium, Jpn J Med Mycol, 36 (Suppl 1) 76, 1995. (in Japanese)
29. Hay RJ: Antifungal drugs - An introduction, J Dermatol Treat, 1 (Suppl 2): 1-3, 1990.
30. Lowe G, Green C, Jennings P: Hepatitis associated with terbinafine treatment, BMJ, 306: 248, 1993.
31. van't Wout JW, Herrmann WA, de Vries RA, Stricker BHCh: Terbinafine associated hepatic injury, J Hepatol, 21: 115-117, 1994.
32. Clayton YM: In vitro activity of terbinafine, Clin Exp Dermatol, 14: 101-103, 1989.
33. Finlay AY, Lever V, Dykes PJ: Nail matrix kinetics of oral terbinafine in onychomycosis and normal nails, J Dermatol Treat, 1 (Suppl 2): 51-53, 1990.
34. Terbinafine Study Group: Clinical evaluation of terbinafine, a new oral antifungal agent, for tinea unguium - An optimal dose and treatment regimen-finding study, Nishinihon J Dermatol, 56: 794-808, 1994. (in Japanese)
35. Terbinafine Study Group: Clinical evaluation of terbinafine-A double-blind clinical trial using griseofulvin as control, Nishinihon J Dermatol, 56: 809-825, 1994. (in Japanese)
36. Matsumoto T, Tanuma H, Kaneko A, Takasu H, Nishiyama S: Clinical and pharmacokinetic evaluation of terbinafine after oral administration to patients with tinea unguium, Nishinihon Jermatol, 56: 374-381, 1994. (in Japanese)
37. Matsumoto T, Tanuma H, Kaneko A, Takasu H, Nishiyama S: Clinical and pharmacokinetic investigation of oral terbinafine in patients with tinea unguium, Mycoses, 38: 135-144, 1995.
38. Zaias N, Serrano L: The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine, Clin Exp Dermatol, 14: 120-123, 1989.
39. Goodfield MJD: Clinical results with terbinafine in onychomycosis, J Dermatol Treat, 1 (Suppl 2): 55-57, 1990.
40. Hoffman H, Bräutigam M, Weidinger G, et al: LAGOS II study group. Treatment of toenail onychomycosis: A randomized, double-blind study with terbinafine and griseofulvin, Arch Dermatol, 131: 919-922, 1995.
41. Haneke EA, Taush I, Bräutigam M: LAGOS III study group short-duration treatment of finger nail dermatophytosis: Randomized double-blind study with terbinafine and griseofulvin, J Am Acad Dermatol, 32: 72-77, 1995.
42. Villas VV, Jones TC: Special features of the clinical use of oral terbinafine in the treatment of fungal disease, Br J Dermatol, 126: 61-96, 1992.
43. Keyser PD, Backer M De, Westelick KJ: A short course of terbinafine (Lamisil®) 250 mg daily in toenail onychomycosis unsuccessfully treated with azole-type drugs. Poster abstracts displayed at a symposium, held on 18 May 1993 in Vienna during Dermatology 2000. CCT Health care communication Limited. London, 1994, pp 44-47.
44. Finlay AY: Pharmacokinetics of terbinafine in the nail, Br J Dermatol, 126 (Suppl 39): 28-32, 1992.
45. Shaw JTB, Tabit MH, Troke FK: Recent Trends in the Discovery Development and Evaluation of Antifungal Agents Fromtling RA (ed), JR Prous, Barcelona, 1987, p 125.
46. Jacobson MA, Hanks DK, Ferrell LD: Fatal acute hepatic necrosis due to fluconazle, Am Acad Dermatol, 96: 188-190, 1994.
47. Noguchi H, Hiruma M, Kawada A, Ishibashi A: Weekly oral dose of 100 mg of fluconazole in treatment of tinea unguium, Jpn J Med Mycol, 35: 169-174, 1994.
48. Montero-Gei, Melendez M, Siles L: Fluconazole in the treatment of onychomycosis. Preliminary results, in: Program and abstracts, 11 th Congress International Society Human Animal Mycology, p 142, Montreal, 1994.
49. Koukkanen K, Alava S: Fluconazole in the treatment of onychomycosis caused by dermatophytes, J Dermatol Treat, 3:115-117, 1992.
50. Nahas GT, Sisto M: Onychomycosis, successful treatment with one-weekly fluconazole, Dermatology, 186: 59-61, 1993.
51. Faergemann J, Laufen H: Level of fluconazole in serum, stratum cornium, epidermis-dermis and eccrine sweat, Clin Exp Dermatol, 18: 102-106, 1993.
52. Botter AA, Nuijten STM: Further experience with ketoconazole in the treatment of onychomycosis, Mykosen, 24: 156-166, 1981.
53. Ketoconazole Study Group in Dermatological Field: A double-blind clinical trial of ketoconazole and griseofulvin for tinea unguium, The Clinical Report, 18: 3487-3500, 1984.
54. Masutani M: Treatment of tinea pedis with a 1% sulconazole solution, The Clinical Report, 26: 2682-2689, 1992.
55. Chiyoya N, Sato S: Treatment of tinea unguium with econazole, The Clinical Report, 21: 431-435, 1987.
56. Reinel D: Topical treatment of onychomycosis with amorolfine 5% nail lacquer, Dermatology, 184: 21-24, 1992.
57. Lauharanta J: Comparative efficacy and safety of amorolfine nail laquer 2% versus 5% once weekly, Clin Exp Dermatol, 17: 41-43, 1992.
58. Reinel D, Clarke C: Comparative efficacy and safety of amorolfine nail lacquer 5% in onychomycosis, once-weekly versus twice-weekly, Clin Exp Dermatol, 17: 44-49, 1992.
59. Yu Baotian: A Clinical and laboratory study of ciclopirox olamine (8% Batrafen) in the treatment of onychomycosis, Chin Med Sci J, 6: 166-168, 1991.
60. Hay RJ, Clayton YM, Moure MK: A comparison of tioconazole 28% nail solution versus base as anadjunct to oral griseofulvin in patients with onychomycosis, Clin Exp Dermatol, 12: 175-177, 1987.
61. Tanuma H, Uemura M, Uezuka M, Nishiyama S: Therapeutic efficacy of a combination of econazole nitrate and a 10% urea ointment for tinea unguium, Journal of New Remedies & Clinics, 36: 1236-1240, 1987.
62. Ohtake N, Shimada S: Clinical efficacy of neticonazole HCl cream for different types of trichophytosis and its clinical application in topical therapy for tinea unguium, The Clinical Report, 29: 3713-3721, 1995.
63. Shinmura Y, Ohoka A, Monma K: Efficacy of topical application of econazole for tinea unguium, Journal of New Remedies & Clinics, 34: 2166-2170, 1985.
64. Ishii M, Hamada T, Asai Y: Combined topical treatment under occulsive dressings of 20% urea ointment and fungicidal agent in tinea unguium, Jpn J Dermatol, 92: 737-742, 1982. (in Japanese)
65. Unno K, Tsuboi Y, Ogawa H: Topical of onychomycosis with bifonazole cream containing 40% urea, Jpn J Med Mycol, 35: 281-286, 1994.
66. Nolting S: Non-traumatic removal of the nail and simultaneous treatment of onychomycosis, Dermatologica, 169: 117-120, 1984.
67. Felten G, Stettendorf S: Topical therapy of onychomycosis with bifonazole-urea cream, Dtsch Dermatol, 35: 1-2, 1987.
68. Lecha V, Martinez C, Mascara JM: Experience with topical application of bifonazole plus urea in the treatment of onychomycosis, J Dermatol Treat, 1: 131-132, 1990.
69. Hay RJ, Roberts DT, Do Herty VR, Richardson A, Midgley G: The topical treatment of onychomycosis using a new combined urea/imidazole preparation, Clin Exp Dermatol, 13: 164-167, 1988.
70. Hardjoko FS, Widyanto S, Singgih M, Susilo J: Treatment of onychomycosis with a bifonazoleurea combination, Mycoses, 33: 167-171, 1990.
71. Nagasaki Tinea Unguium Study Group: Treatment of tinea unguium by the occlusive dressing technique using butenafine HCl cream, Nishinihon J Dermatol, 56: 1072-1078, 1994.
72. Shoji A, Go K, Tokushima Y: Phase II clinical trial of TJN-318 solution for tinea unguium, The Clinical Report, 28: 1091-1100, 1994.
73. Akiba H: Treatment of tinea unguium by nail extraction, rinsho derma (Tokyo), 37: 1391-1394, 1995. (in Japanese)
74. Horiguchi Y, Ozaki M, Ofuji S, Furukawa F: Efficacy of a combination of nail extraction and urea ointment for ungual mycosis, Acta Dermatologica, 77: 97-102, 1982.
75. Mori T: Treatment of impacted nails and tinea unguium by nail abrasion,rinsho derma (Tokyo), 37: 579-582, 1995. (in Japanese)
76. Shoji A: Tinea unguium (VIII) - 3. Surgical treatment, rinsho derma (Tokyo), 33: 1183-1184, 1991. (in Japanese)
77. Rothermal E, Apfelberg DB: Carbon dioxide laser use for certain diseases of the toenails, Clin Podiatr Med Surg, 4:809-821, 1987.
78. Backer M De, Keyser P De, Vroey C De and Lesaffre: A 12-week treatment for dermatophytes toe onychomycosis: Terbinafine 250 mg/day vs. itraconazole 200 mg/day - A double-blind comparative trial, Br J Dermatol, 134 (Suppl 46): 16-17, 1996.
79. Bräutigam M, Nolting S, Schopf RE, Weidinger G: German randomized doubled-blind multicentre comparison of terbinafine and itraconazole for the treatment of toenail tinea infection, Br J Dermatol, 134 (Suppl 46): 18-21, 1996.